---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-006885"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T01:01:49.338618+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Aptose TUSCANY abstract accepted for ASH 2025 poster session

## Summary
- Abstract #1645 from TUSCANY trial of tuspetinib + venetoclax + azacitidine in newly diagnosed AML selected for ASH 2025 poster presentation.
- Poster session December 6, 2025, 5:30-7:30 PM in Orlando, FL.
- Abstract available now; additional data to be presented in the poster.
- Aptose developing tuspetinib-based triple therapy for patients ineligible for induction chemo.

## SEC filing metadata
- accession: 0001171843-25-006885
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325006885/0001171843-25-006885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325006885/f8k_103125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-006885
- JSON: https://secwatch.observer/filing/0001171843-25-006885.json
- Plain text: https://secwatch.observer/filing/0001171843-25-006885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.